Tarsus to Present at Upcoming Investor Conferences

Rhea-AI Summary

Tarsus Pharmaceuticals (NASDAQ: TARS) announced its participation in two major healthcare conferences on March 16, 2022. The company will engage in a virtual fireside chat at the Oppenheimer’s 32nd Annual Healthcare Conference at 9:40am PT and a corporate presentation at the Barclays Global Healthcare Conference at 1:50pm PT. Tarsus focuses on innovative treatments in eye care and other therapeutic categories, with investigational products in clinical trials addressing significant unmet needs. Live webcasts will be available on their website.

IRVINE, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced management will present at the following conferences:

• Oppenheimer’s 32^nd Annual Healthcare Conference on Wednesday, March 16, 2022
  • Virtual Fireside Chat at 9:40am PT / 12:40pm ET

• Barclays Global Healthcare Conference 2022 on Wednesday, March 16, 2022
  • In-person Corporate Presentation at 1:50pm PT / 4:50pm ET

The above listed date and times are subject to change. Details on the presentation times or changes to the presentation date can be found on the Company's website. Please check www.tarsusrx.com for the latest information.

A live webcast of the presentations will also be available on the events section of the Tarsus website. The replay will be available within 48 hours and will be archived for a limited time.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. It is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. The company is studying two investigational medicines in clinical trials. Its lead product candidate, TP-03, is a novel therapeutic being studied in a second Phase 3 pivotal trial for the treatment of Demodex blepharitis. TP-03 is also being developed for the treatment of Meibomian Gland Disease. Tarsus is developing TP-05, an oral, non-vaccine therapeutic for the prevention of Lyme disease, which is currently being studied in a Phase 1b clinical trial.

Contacts:
Media Contact:
SuJin Oh
twelvenote
(917) 841-5213
soh@twelvenote.com

Investor Contact:
David Nakasone
Head of Investor Relations
(949) 620-3223
DNakasone@tarsusrx.com

FAQ

What conferences will Tarsus Pharmaceuticals participate in on March 16, 2022?

Tarsus Pharmaceuticals will participate in Oppenheimer’s 32nd Annual Healthcare Conference and the Barclays Global Healthcare Conference on March 16, 2022.

What is the schedule for Tarsus Pharmaceuticals at the Oppenheimer conference?

Tarsus Pharmaceuticals will have a virtual fireside chat at the Oppenheimer conference at 9:40am PT on March 16, 2022.

At what time will Tarsus Pharmaceuticals present at the Barclays conference?

Tarsus Pharmaceuticals will present in person at the Barclays Global Healthcare Conference at 1:50pm PT on March 16, 2022.

Where can I find updates about Tarsus Pharmaceuticals' presentations?

Updates regarding Tarsus Pharmaceuticals' presentations can be found on their website.

Will there be a live broadcast of Tarsus Pharmaceuticals' presentations?

Yes, Tarsus Pharmaceuticals will provide a live webcast of their presentations, which will also be available for replay on their website.